Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma

The treatment landscape of metastatic renal cell carcinoma (mRCC) has been transformed with the advent of antiangiogenics, notably tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptor (VEGFR), and immune checkpoint inhibitors (ICIs). Both treatment options have imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Rassy, Elie, Flippot, Ronan, Albiges, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Challenging Dogma: New Evidence to Guide Practice in Urologic Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081462/
https://www.ncbi.nlm.nih.gov/pubmed/32215057
http://dx.doi.org/10.1177/1758835920907504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081462/
https://www.ncbi.nlm.nih.gov/pubmed/32215057
http://dx.doi.org/10.1177/1758835920907504

Ejemplares similares